Detailed narrative
Commercial Readiness for Ulixacaltamide
Praxis is ramping up commercial efforts for Ulixacaltamide, with a PDUFA date of January 29, 2027. The commercial leadership team is in place, and plans are underway for field force hiring and training in advance of the launch. The company is expanding its commercial infrastructure across operations, marketing, access, and compliance, and has successfully established a distribution network to ensure drug availability upon potential approval.
Physician and Patient Validation for Ulixacaltamide
An extensive observational study involving over 2,300 U.S. physicians and 1,300 ET patients validated Ulixacaltamide's profile across efficacy, breadth of benefits, and tolerability. These results reinforced the drug's potential for over $10 billion in peak sales and the significant unmet need in the market. The company also highlighted its robust presence at the American Academy of Neurology Annual Meeting, with 15 scientific presentations, including a plenary presentation on the Essential3 program results.
Relutrigine for DEE Programs
The FDA has accepted relutrigine's NDA with priority review for seizures associated with SCN2A & 8A-DEE, setting a PDUFA date of September 27, 2026. Commercial preparations are advancing, including hiring, inventory building, patient support programs, and payer engagement. Additionally, recruitment for the EMBOLD study in the broader DEE population has been completed in record time, with top-line results expected in Q4 2026, which could significantly expand relutrigine's commercial potential.
Vormatrigine Program Updates
Vormatrigine, described as the most potent and selective sodium channel modulator for epilepsy, has several key milestones approaching. The readout of the POWER1 Phase III study is expected later this quarter. The company plans to initiate the POWER3 study, a monotherapy trial, in the near future. Enrollment for the POWER2 Phase III study, which evaluates 20, 30, and 40 milligrams once daily, is progressing well, with completion expected by year-end and readout early next year.
Elsunersen (ASO Platform) Progress
Praxis reported positive results from EMBRAVE Part A for easinersen, the first ASO on its platform, for SCN2A early onset DEE. The study, which enrolled 9 children, demonstrated a 77% placebo-adjusted reduction in monthly seizures and disease-modifying components across multiple domains, while maintaining a generally safe and well-tolerated profile. These results, combined with open-label extension data, underscore the drug's transformational potential.
Essential Tremor Market Dynamics and Awareness
Of the 7 million Americans living with essential tremor, approximately 2 million are in immediate need of therapy. The gap between the prevalent population and those seeking treatment is attributed to the progressive nature of the disease, societal stigma, and a historical lack of effective treatments. Praxis has launched the 'Essential to Me' disease state campaign to raise awareness and encourage patients to seek treatment, aiming to change these dynamics.